HT
ADIL

Headlands Technologies’s Adial Pharmaceuticals ADIL Stock Holding History

Headlands Technologies’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3
Closed -$85 – 1111
2024
Q1 		$85 Buy
+3
New +$112 ﹤0.01% 1215

Other funds holding ADIL

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
1IA
1620 Investment Advisors Plymouth, Massachusetts $161M AUM 30.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Headlands Technologies's ADIL Position: Q2 2024 in Review

Headlands Technologies sold out of Adial Pharmaceuticals (ADIL) in Q2 2024, closing a stake of 3 shares — an estimated $85 sold.

Headlands Technologies first reported a position in ADIL in Q1 2024 and held it in 1 quarter. The position peaked at $85 in Q1 2024. 14 funds tracked by Wall St. Rank hold ADIL as of Q2 2024.

  • Headlands Technologies reported no remaining Adial Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Headlands Technologies sold 3 Adial Pharmaceuticals shares in Q2 2024, an estimated $85.
  • Headlands Technologies first reported a position in Adial Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Headlands Technologies's Adial Pharmaceuticals position peaked at $85 in Q1 2024.
  • 14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2024.

Based on Headlands Technologies's 13F filing for Q2 2024, filed 7 Aug 2024.